Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Is Abbott's January Pullback a Good Time to Buy? Reported by Thomas Hughes. Posted: 1/24/2026. 
What You Need to Know - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback makes the stock look attractively valued. The move—driven more by market angst than by any clear fundamental weakness—feels like a knee-jerk overreaction that has pushed the shares back into a buy zone. 
Gold is soaring, but while the media hypes price predictions, there's one gold income opportunity no one's talking about. It's not a mining stock, not an option trade, and not physical gold you have to store. A quiet fund trading for just $15 has been delivering up to $1,152 a month to regular investors. It's a smarter, faster way to ride gold's surge and get paid monthly while you do it. Discover the gold income breakthrough most investors are missing. The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The worst that can be said about Abbott Laboratories' Q4 results and guidance is that some metrics missed the most bullish expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. Segment results highlighted the resilience of Abbott's diversified healthcare portfolio. The Nutrition and Diagnostics segments contracted—Nutrition declined nearly 9%—but gains in Established Pharmaceuticals and Med Tech more than offset those declines. The pharma segment grew about 9%, led by generics and strength in emerging markets, while Med Tech rose roughly 12.3%, with broad-based strength across subsegments. Margins improved and were roughly in line with analyst expectations. A shift in product mix, strength in Med Tech, lower COVID-19-related sales and operational improvements supported margins. Looking ahead, the company expects earnings to grow around 10% in 2026, outpacing revenue growth and supporting its capital-return plans. Abbott's capital returns are central to the investment case. The company is a Dividend King, having raised its payout for more than 50 consecutive years, and it should have the capacity to continue doing so. After the pullback, the stock yields roughly 2.5%, and Abbott's payout ratio is under 50% of consensus earnings, leaving room for share buybacks, which help offset dilution from equity-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or price-target changes the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth. The MarketBeat consensus share price target implies as much as ~30% upside from current levels, potentially setting new all-time highs; even the low-end targets suggest modest upside. Key catalysts include an expanding Med Tech portfolio, broader AI integration across operations and products, margin expansion, and M&A. The planned acquisition of Exact Sciences is one example of how Abbott is expanding its revenue and profit streams and bolstering its product pipeline. The recent decline in Abbott's share price has been sharp and could deepen, but institutional investors accumulated shares throughout 2025 and are likely buyers at these discounted levels. Early technical support appears in the $105–$110 range, though it is not yet confirmed. The risk remains that ABT could drift to the low end of the buy zone before recovering, potentially testing the ~$95 level or lower.
| 
